Orasis Pharmaceuticals – Weekly Recap

Orasis Pharmaceuticals is an ophthalmic-focused biopharmaceutical company developing treatments for presbyopia, a common age-related loss of near-vision affecting a large and growing global population. This weekly recap reviews the latest clinical and commercial developments surrounding its lead product, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, and examines how newly presented data may influence the company’s market position and future prospects.

During the week, Orasis highlighted new independent clinical data on pilocarpine presented by researchers from the Bascom Palmer Eye Institute at the Hawaiian Eye & Retina 2026 conference. The findings underscored that pilocarpine’s effects are concentration-dependent, with lower-concentration formulations potentially offering a more favorable balance between efficacy and tolerability for presbyopia patients. Orasis used this context to reinforce the strategic rationale behind Qlosi’s low-concentration formulation and the importance of careful formulation design in optimizing patient outcomes.

More specifically, Orasis released detailed imaging study results demonstrating that Qlosi’s 0.4% pilocarpine formulation exhibits a “pupil-selective” profile. In the study, Qlosi significantly reduced pupil diameter to improve near vision while showing ciliary muscle movement comparable to a balanced salt solution control. By contrast, a 2% pilocarpine formulation produced statistically significant ciliary muscle activation, which is more closely associated with accommodative spasm and related side effects. This distinction supports Orasis’s claim that Qlosi can deliver the near-vision benefit via a pinhole effect without materially engaging the accommodative apparatus.

The company also pointed to real-world safety experience from the first 10 months of Qlosi’s commercial use, reporting no serious adverse events and no retinal detachments. This safety profile, combined with the preservative-free, low-concentration design, strengthens Qlosi’s positioning as a treatment suitable for long-term use in the underpenetrated global presbyopia market. Clinically, the new data provide prescribers with additional evidence that may address concerns about safety associated with higher-concentration miotics.

From a market and strategic standpoint, these developments enhance Orasis’s ability to differentiate Qlosi from competing presbyopia drops, particularly higher-dose pilocarpine products. The reinforced safety and mechanism-of-action data could support broader physician adoption, improve payer receptivity, and bolster the company’s narrative as it seeks to expand Qlosi’s commercial footprint in the U.S. and potentially in ex-U.S. markets through partners or future strategic collaborations. While no new regulatory or revenue figures were disclosed, the week’s news solidified Orasis’s scientific and clinical positioning in the competitive presbyopia landscape, marking a positive and strategically important period for the company.